D
Dong Wan Kim
Researcher at Seoul National University Hospital
Publications - 880
Citations - 61091
Dong Wan Kim is an academic researcher from Seoul National University Hospital. The author has contributed to research in topics: Lung cancer & Crizotinib. The author has an hindex of 89, co-authored 833 publications receiving 49632 citations. Previous affiliations of Dong Wan Kim include University of California, Irvine & Korea University.
Papers
More filters
Journal ArticleDOI
Safety and efficacy of pralsetinib in patients with advanced RET fusion-positive non-small cell lung cancer: Update from the ARROW trial.
Giuseppe Curigliano,Justin F. Gainor,Frank Griesinger,Michael Thomas,Vivek Subbiah,Christina S. Baik,Daniel Shao-Weng Tan,Dae Ho Lee,Daniel Misch,Elena Garralda,Dong Wan Kim,Luis Paz-Ares,Julien Mazieres,Stephen V. Liu,Gregory P. Kalemkerian,Yariv Houvras,Daniel W. Bowles,Aaron S. Mansfield,Alena Zalutskaya,Anthonie J. van der Wekken +19 more
TL;DR: ARROW (NCT03037385) supported the US FDA approval of pralsetinib, a highly potent oral oncogenic driver in non-small cell lung cancer (NSCLC), by donating $1.9089 to Janssen Pharmaceuticals, Inc.
Journal ArticleDOI
Morphological evolution of CdS nanowires to nanosheets.
TL;DR: A three-step process for the morphological evolution of CdS nanowires to nanosheets is proposed; (1) nucleation and growth of nanowire by vapor-liquid-solid mechanism, (2) side-branching of secondary nanoweires perpendicular to the originalnanowires and filling between them by Vapor-Solid mechanism, and finally (3) formation of nanOSheets through the repetition of side- Branching and filling processes.
Journal ArticleDOI
Efficacy of Pemetrexed-based Chemotherapy in Comparison to Non-Pemetrexed-based Chemotherapy in Advanced, ALK+ Non-Small Cell Lung Cancer
Jaemin Jo,Se Hyun Kim,Yu Jung Kim,Ju Hyun Lee,Miso Kim,Bhumsuk Keam,Tae Min Kim,Dong Wan Kim,Dae Seog Heo,Jin Haeng Chung,Yoon Kyung Jeon,Jong Seok Lee +11 more
TL;DR: Pemetrexed-based regimens may prolong PFS in patients with ALK+ NSCLC as a first-line treatment, but the lack of exposure to second-generation ALK inhibitors and intracranial metastasis on initial diagnosis are not associated with prolonged OS.